Terms: = Leukemia AND GATA1, ERYF1, P15976, 2623, ENSG00000102145, NFE1, GF1 AND Treatment
110 results:
1. GAS5 promotes cytarabine induced myelosuppression via inhibition of hematopoietic stem cell differentiation.
Du YX; Yang J; Yan H; Liu YL; Chen XP
Toxicol Appl Pharmacol; 2024 Feb; 483():116841. PubMed ID: 38290668
[TBL] [Abstract] [Full Text] [Related]
2. Too many white cells-TAM, JMML, or something else?
Satty A; Stieglitz E; Kucine N
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):37-42. PubMed ID: 38066851
[TBL] [Abstract] [Full Text] [Related]
3. Down syndrome and leukemia: An insight into the disease biology and current treatment options.
Barwe SP; Kolb EA; Gopalakrishnapillai A
Blood Rev; 2024 Mar; 64():101154. PubMed ID: 38016838
[TBL] [Abstract] [Full Text] [Related]
4. Perspectives of current understanding and therapeutics of Diamond-Blackfan anemia.
Liu Y; Karlsson S
Leukemia; 2024 Jan; 38(1):1-9. PubMed ID: 37973818
[TBL] [Abstract] [Full Text] [Related]
5. Detection of transient abnormal myelopoiesis blasts in a liver biopsy specimen by double-immunostaining for full-length gata1 and CD42b.
Haba A; Imaizumi Y; Hayashi D; Yasue S; Otsuka H; Endo S; Ozeki M; Kobayashi K; Miyazaki T; Hara A; Ohnishi H
Hematology; 2023 Dec; 28(1):2240135. PubMed ID: 37489937
[TBL] [Abstract] [Full Text] [Related]
6. Leukemogenesis in infants and young children with trisomy 21.
Roberts I
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):1-8. PubMed ID: 36485097
[TBL] [Abstract] [Full Text] [Related]
7. Activin A downregulates the CD69-MT2A axis via p38MAPK to induce erythroid differentiation that sensitizes BCR-ABL-positive cells to imatinib.
Chen CW; Huang NK; Lee YL; Fan CK; Chen YC; Liu CW; Huang HM
Exp Cell Res; 2022 Aug; 417(2):113219. PubMed ID: 35643179
[TBL] [Abstract] [Full Text] [Related]
8. Hirsutine, a novel megakaryopoiesis inducer, promotes thrombopoiesis via MEK/ERK/FOG1/TAL1 signaling.
Kang Y; Lin J; Wang L; Shen X; Li J; Wu A; Yue L; Wei L; Ye Y; Yang J; Wu J
Phytomedicine; 2022 Jul; 102():154150. PubMed ID: 35569185
[TBL] [Abstract] [Full Text] [Related]
9. Acute myeloid leukemia with an
Rosenzweig J; Pillai PM; Prockop S; Benayed R; Eidenschink Brodersen L; Najfeld V; Loken MR; Zhang Y; Shukla N
Cold Spring Harb Mol Case Stud; 2022 Apr; 8(3):. PubMed ID: 35483876
[TBL] [Abstract] [Full Text] [Related]
10. The paradox of Myeloid leukemia associated with Down syndrome.
Gupte A; Al-Antary ET; Edwards H; Ravindranath Y; Ge Y; Taub JW
Biochem Pharmacol; 2022 Jul; 201():115046. PubMed ID: 35483417
[TBL] [Abstract] [Full Text] [Related]
11. Hematological disorders in children with Down syndrome.
Triarico S; Trombatore G; Capozza MA; Romano A; Mastrangelo S; Attinà G; Maurizi P; Ruggiero A
Expert Rev Hematol; 2022 Feb; 15(2):127-135. PubMed ID: 35184659
[TBL] [Abstract] [Full Text] [Related]
12. Functional Evaluation of KEL as an Oncogenic Gene in the Progression of Acute Erythroleukemia.
Liu W; Wu Z; Yu Y; Qiao C; Zhu H; Hong M; Zhu Y; Qian S; Chen S; Wu D; Li J; Jin H
Oxid Med Cell Longev; 2022; 2022():5885342. PubMed ID: 35140839
[TBL] [Abstract] [Full Text] [Related]
13. Clinical and biological aspects of myeloid leukemia in Down syndrome.
Boucher AC; Caldwell KJ; Crispino JD; Flerlage JE
Leukemia; 2021 Dec; 35(12):3352-3360. PubMed ID: 34518645
[TBL] [Abstract] [Full Text] [Related]
14. TGF-β1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis.
Varricchio L; Iancu-Rubin C; Upadhyaya B; Zingariello M; Martelli F; Verachi P; Clementelli C; Denis JF; Rahman AH; Tremblay G; Mascarenhas J; Mesa RA; O'Connor-McCourt M; Migliaccio AR; Hoffman R
JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34383713
[TBL] [Abstract] [Full Text] [Related]
15. Pharmacologic targeting of the P-TEFb complex as a therapeutic strategy for chronic myeloid leukemia.
Qing Y; Wang X; Wang H; Hu P; Li H; Yu X; Zhu M; Wang Z; Zhu Y; Xu J; Guo Q; Hui H
Cell Commun Signal; 2021 Aug; 19(1):83. PubMed ID: 34372855
[TBL] [Abstract] [Full Text] [Related]
16. High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial.
Hitzler J; Alonzo T; Gerbing R; Beckman A; Hirsch B; Raimondi S; Chisholm K; Viola S; Brodersen L; Loken M; Tong S; Druley T; O'Brien M; Hijiya N; Heerema-McKenney A; Wang YC; Schore R; Taub J; Gamis A; Kolb EA; Berman JN
Blood; 2021 Dec; 138(23):2337-2346. PubMed ID: 34320162
[TBL] [Abstract] [Full Text] [Related]
17. Cabozantinib promotes erythroid differentiation in K562 erythroleukemia cells through global changes in gene expression and JNK activation.
Fu YH; Ou DL; Yang YR; Su KW; Chen CY; Tien HF; Lai ZS; Shen CJ; Chien HF; Lin LI
Cancer Gene Ther; 2022 Jun; 29(6):784-792. PubMed ID: 34117374
[TBL] [Abstract] [Full Text] [Related]
18. Clinical impact of genomic characterization of 15 patients with acute megakaryoblastic leukemia-related malignancies.
Lalonde E; Rentas S; Wertheim G; Cao K; Surrey LF; Lin F; Zhao X; Obstfeld A; Aplenc R; Luo M; Li MM
Cold Spring Harb Mol Case Stud; 2021 Apr; 7(2):. PubMed ID: 33832921
[TBL] [Abstract] [Full Text] [Related]
19. [Analysis of Clinical Characteristics and Prognosis in Children with Acute Megakaryoblastic leukemia without Down Syndrome].
Lin SF; Guo SY; Liu S; Wang J; Huang K; Li Y; Fang JP; Zhou DH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):374-380. PubMed ID: 33812402
[TBL] [Abstract] [Full Text] [Related]
20. HMGCS1 drives drug-resistance in acute myeloid leukemia through endoplasmic reticulum-UPR-mitochondria axis.
Zhou C; Li J; Du J; Jiang X; Xu X; Liu Y; He Q; Liang H; Fang P; Zhan H; Zeng H
Biomed Pharmacother; 2021 May; 137():111378. PubMed ID: 33601148
[TBL] [Abstract] [Full Text] [Related]
[Next]
